{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:58:05Z","timestamp":1789671485933,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.eururo.2013.09.005","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T02:58:43Z","timestamp":1379645923000},"page":"875-883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy"],"prefix":"10.1016","volume":"65","author":[{"given":"Peter F.A.","family":"Mulders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.09.005_bib0005","series-title":"World population prospects: the 2010 revision, highlights and advance tables","year":"2010"},{"key":"10.1016\/j.eururo.2013.09.005_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2013.09.005_bib0015","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/cncr.26392","article-title":"Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.09.005_bib0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.seminoncol.2011.01.011","article-title":"Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum","volume":"38","author":"Sajid","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11864-011-0160-6","article-title":"Treating prostate cancer in elderly men: how does aging affect the outcome?","volume":"12","author":"Shelke","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0030","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ctrv.2009.04.014","article-title":"Treatment of prostate cancer in unfit senior adult patients","volume":"35","author":"Falci","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2013.09.005_bib0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.22495","article-title":"A pilot study of the Vulnerable Elders Survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation","volume":"109","author":"Mohile","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2013.09.005_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of age at diagnosis on prostate cancer treatment and survival","volume":"29","author":"Bechis","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0045","doi-asserted-by":"crossref","first-page":"E826","DOI":"10.1111\/j.1464-410X.2012.11206.x","article-title":"Current role of diethylstilbestrol in the management of advanced prostate cancer","volume":"110","author":"Bosset","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.09.005_bib0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.09.005_bib0055","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0060","unstructured":"Harland S, de Bono JS, Haqq C, et al. Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: results from the COU-AA-301 phase 3 study. Paper presented at: European Multidisciplinary Cancer Congress (ECCO ESMO ESTRO); September 23\u201326, 2011; Stockholm, Sweden."},{"key":"10.1016\/j.eururo.2013.09.005_bib0065","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0070","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/annonc\/mds585","article-title":"Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy","volume":"24","author":"Sternberg","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0075","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.eururo.2008.07.078","article-title":"Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer","volume":"55","author":"Italiano","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0080","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/annonc\/mdq050","article-title":"Docetaxel-based combination therapy for castration-resistant prostate cancer","volume":"21","author":"Galsky","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0085","first-page":"CD005247","article-title":"Chemotherapy for hormone-refractory prostate cancer","author":"Shelley","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.09.005_bib0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(06)00566-0","article-title":"Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies","volume":"176","author":"Halabi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","article-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","volume":"61","author":"Armstrong","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0100","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000277592","article-title":"Prognostic factors affecting progression and survival in metastatic prostate cancer","volume":"84","author":"Nayyar","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2013.09.005_bib0110","unstructured":"Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin. Paper presented at: European Cancer Congress; September 27\u2013October 1, 2013; Amsterdam, The Netherlands."},{"key":"10.1016\/j.eururo.2013.09.005_bib0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-012-2001-0","article-title":"Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer","volume":"71","author":"Chi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3816\/CGC.2003.n.025","article-title":"Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years","volume":"2","author":"Beer","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.eururo.2013.09.005_bib0125","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.09.005_bib0130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2147\/CIA.S1395","article-title":"Docetaxel treatment in the elderly patient with hormone refractory prostate cancer","volume":"2","author":"Sinibaldi","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.eururo.2013.09.005_bib0135","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.09.005_bib0140","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0145","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2013.09.005_bib0150","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.09.005_bib0155","unstructured":"Sternberg CN. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Paper presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14\u201316, 2013; Orlando, FL, USA."},{"key":"10.1016\/j.eururo.2013.09.005_bib0160","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1200\/jco.2012.30.5_suppl.9","article-title":"Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA) [abstract]","volume":"30","author":"Sartor","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.09.005_bib0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.09.005_bib0170","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813009925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813009925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T04:18:09Z","timestamp":1563941889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813009925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0302283813009925"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.09.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2013.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}